Key result
Dipyridamole inhibited platelet adhesiveness and ADP-induced aggregation in vitro at 100-500 µg/ml and in vivo following intravenous or oral administration.
Why the study?
Does dipyridamole inhibit platelet adhesiveness and aggregation in human platelets?
Does dipyridamole inhibit platelet adhesiveness and aggregation in human platelets?
Dipyridamole demonstrates dose-dependent inhibition of platelet adhesiveness and aggregation, providing mechanistic insight into its antiplatelet effects.
No takes yet. Share an insight, caveat, or question.
Supports antiplatelet effects in animals; leaves open translation to human platelet inhibition.
Endo et al. (1977) studied Platelet adhesiveness and aggregation. Dipyridamole vs. Baseline/control was evaluated on Platelet adhesiveness and aggregation. Dipyridamole inhibited platelet adhesiveness and ADP-induced aggregation in vitro at 100-500 µg/ml and in vivo following intravenous or oral administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: